期刊文献+

冠状动脉慢血流现象相关因素和前列地尔注射液疗效的分析 被引量:2

下载PDF
导出
摘要 目的:探讨慢血流发生的相关危险因素,并观察前列地尔注射液治疗冠脉慢血流现象(CSFP)的临床疗效。方法:经CAG证实存在慢血流现象,但以冠状动脉无明显病变的42例患者作为慢血流组,并随机选取相同时期CAG显示远端血流灌注无延迟,且冠状动脉无明显病变的42例患者作为对照组,比较2组间各项临床指标的差异。再将42例CSFP患者按完全随机方法分成对照组和治疗组各21例,对照组采用常规硝酸酯类药物加阿司匹林治疗,治疗组(21例)在对照组治疗基础上加用前列地尔注射液治疗。观察2组治疗前后胸痛症状的改善及复查冠脉造影时冠脉血流的变化。结果:2组患者在性别、年龄、心率、血压、血糖、血脂、饮酒史等临床方面无统计学差异;而慢血流组有吸烟史的患者高于对照组,慢血流组血小板平均容积(MVP)水平高于对照组(P<0.01)。治疗组胸痛症状明显改善,有效率为76.2%,对照组的有效率为33.3%(P<0.01);冠脉造影显示2组患者的CTFC(校正的TIMI帧数)较治疗前均明显降低(P<0.01),前列地尔治疗组比对照组下降更明显(P<0.01)。结论:MVP增高可能是慢血流发生的一个危险因素,前列地尔注射液治疗CSFP有较好的疗效。
作者 梁伟东 钟毅
出处 《内科急危重症杂志》 2014年第1期36-38,共3页 Journal of Critical Care In Internal Medicine
  • 相关文献

参考文献18

  • 1Gibson CM,Cannon CP,Daley WL,et al.TIMI frame count:a quantitative method of assessing coronary artery flow[J].Circulation,1996,93 (5):879-888.
  • 2Tambe AA,Demany MA,Zimmerman HA,et al.Angina pectoris and slow flow velocity of dye in coronary arteries——a new angiographic finding[J].Am Heart J,1972,84(1):66-71.
  • 3Beltrame JF,Limaye SB,Horowitz JD.The coronary slow flow phenomenon——a new coronary microvascular disorder[J].Cardiology,2002,97 (4):197-202.
  • 4Diver DJ,Bier JD,Ferreira PE,et al.Clinical and arteriographic characterization of patients with unstable angina without critical coronary arterial narrowing (from the TIMI-ⅢA Trial)[J].Am J Cardiol,1994,74(6):531-537.
  • 5Pekdemir H,Cin VG,Cicek D,et al.Slow coronary flow may be a sign of diffuse atherosclerosis[J].Acta Cardiol,2004,59 (2):127-133.
  • 6Sen N,Basar N,Maden O,et al.Increased mean platelet volume in patients with slow coronary flow[J].Platelets,2009,20(1):23-28.
  • 7Nurkalem Z,Alper AT,Orhan AL,et al.Mean platelet volume in patients with slow coronary flow and its relationship with clinical presentation[J].Turk Kardiyol Dern Ars,2008,36 (6):363-367.
  • 8Yilmaz H,Demir I,Uyar Z.Clinical and coronary angiographic characteristics of patients with coronary slow flow[J].Acta Cardio1,2008,63 (5):579-584.
  • 9Mangieri E,Macchiarelli G,Ciavolella M,et al.Slow coronary flow:clinical and histopathological features in patients with otherwise normal epicardial coronary arteries[J].Cathet Cardiovasc Diagn,1996,37(4):375-381.
  • 10陈修,陈维洲,曾贵云.心血管药理学[M].第2版.北京:北京人民卫生出版社,1996.84-86.

二级参考文献18

  • 1叶云,杨宇,韩卓辉,刘军.前列地尔脂微球载体注射液预防老年人造影剂肾病的临床观察[J].中国新药杂志,2006,15(16):1386-1389. 被引量:8
  • 2Dangas G, Iakovou I, Nikolsky E, et al. Contrast-induced nephropathy after percutaneous coronary interventions in relation to chronic kidney disease and hemodynamic variables. Am J Cardiol, 2005,95 : 13-19.
  • 3Laville M, Juillard L. Contrast-induced acute kidney injury: how should at risk patients be identified and managed? J Nephrol, 2010,23 : 387-398.
  • 4Zoungas S, Ninomiya T, Huxley R, et al. Systematic review:sodium bicarbonate treatment regimens for the prevention of contrast-induced nephropathy. Ann Intern Med, 2009, 151: 631- 638.
  • 5Rihal CS, Textor SC, Grill DE, et al. Incidence and prognostic importance of acute renal failure after percutaneous coronary intervention. Circulation, 2002,105 : 2259-2264.
  • 6Tumlin J,Stacul F,Adam A,et al. Pathophysiology of contrastinduced nephropathy. Am J Cardiol, 2006,98 : 14K-20K.
  • 7Solomon R. Preventing contrast-induced nephropathy: problems, challenges and future directions. BMC Med, 2009,7 : 24.
  • 8Sketch MH Jr,Whelton A,Schollmayer E,et al. Prostaglandin E1 Study Group: Prevention of contrast media-induced renal dysfunction with prostaglandin E l:a randomized,double-blind, placebo controlled study. Am J Ther, 2001,8 : 155-162.
  • 9Resnic FS, Wainstein M, Lee MK, et al. No-reflow is an inde- pendent predictor of death and myocardial infarction after per- cutaneous coronary intervention. Am Heart J, 2003,145,9-11.
  • 10Inserte J, Garcia Dorado D, Hernando V, et al. Ischemic pre condition ing prevents calpainmediated impairment of Na4 /k+ ATPase activity during early reperfusion. Cardiovase Res, 2006,70:364 373.

共引文献17

同被引文献13

二级引证文献7

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部